Sign In
Buy PRFX
$1.13
+0.130 (+13.00%)
At Close: Aug 04, 2026
TEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
12:12pm, Tuesday, 27'th May 2025
As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—B
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European indep
TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, tod
PainReform Provides Year-End Business Update
05:00pm, Monday, 07'th Apr 2025
TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established ther
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
11:00am, Wednesday, 05'th Mar 2025
Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainRef
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
08:30am, Tuesday, 18'th Feb 2025
DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains comm
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
08:30am, Friday, 27'th Dec 2024
TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
08:30am, Wednesday, 20'th Nov 2024
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
05:00pm, Thursday, 07'th Nov 2024
TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
08:30am, Wednesday, 11'th Sep 2024
Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain M
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
09:46am, Tuesday, 10'th Sep 2024
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
08:30am, Tuesday, 20'th Aug 2024
TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
10:00am, Wednesday, 07'th Aug 2024
TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
08:30am, Thursday, 01'st Aug 2024
New process expected to significantly bolster future commercialization efforts New process expected to significantly bolster future commercialization efforts
